Edition:
United Kingdom

Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

39.69USD
20 Apr 2018
Change (% chg)

$0.42 (+1.07%)
Prev Close
$39.27
Open
$39.39
Day's High
$39.80
Day's Low
$38.99
Volume
301,626
Avg. Vol
339,906
52-wk High
$45.79
52-wk Low
$11.30

Select another date:

Wed, Mar 21 2018

BRIEF-Arena Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

* ARENA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Arena Pharmaceuticals To Offer 7.5 Mln Shares Of Its Common Stock In An Underwritten Public Offering

* ARENA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Arena Pharma's bowel disease drug meets study goal, shares surge

Arena Pharmaceuticals Inc said on Monday a higher dose of its experimental drug succeeded in improving symptoms associated with ulcerative colitis, a chronic bowel disease, in a mid-stage study, sending its shares up 24 percent.

UPDATE 1-Arena Pharma's bowel disease drug meets study goal, shares surge

March 19 Arena Pharmaceuticals Inc said on Monday a higher dose of its experimental drug succeeded in improving symptoms associated with ulcerative colitis, a chronic bowel disease, in a mid-stage study, sending its shares up 24 percent.

BRIEF-Arena Pharmaceuticals Q4 Loss Per Share $0.35

* ARENA PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

BRIEF-Arena Pharma, Everest Medicines Enter Into Development And Commercialization Partnership For Ralinepag And Etrasimod In China

* ARENA PHARMACEUTICALS AND EVEREST MEDICINES ENTER INTO DEVELOPMENT AND COMMERCIALIZATION PARTNERSHIP FOR RALINEPAG AND ETRASIMOD IN CHINA

BRIEF-Arena Pharmaceuticals reports Q3 loss per share $0.86

* Arena Pharmaceuticals provides corporate update and reports third quarter 2017 financial results

Select another date: